Turbine, a London, UK-based company that uses cell simulations to guide biopharma R&D, raised additional €5.5M in Additional Series A funding.
The round, which brought the total amount to €25.5M, was led by MassMutual Ventures (MMV).
The company intends to use the funds to advance its internal pipeline of simulation-guided programs, while scaling its biology simulation platform to support additional partnerships.
Founded in 2015 by Kristof Szalay, Ph.D., Daniel Veres, M.D., Ph.D., Szabolcs Nagy and Ivan Fekete, M.D., Turbine uses cell simulations to guide biopharma R&D and bring the right drug to every patient in need. Its simulations can represent patient populations that existing biological models cannot. They also have the capacity to perform assays that would be impractical to conduct at scale and with high throughput. A proprietary closed-loop learning process validates promising hypotheses in Turbine’s in vitro and in vivo assays.
Supported by companies such as Bayer and MSD (Merck & Co., Inc., Rahway NJ, USA), Turbine has multiple in vivo validated novel assets in its proprietary and partnered pipeline.
The company also has offices in Budapest, Hungary, and Cambridge, UK.
FinSMEs
20/06/2023